DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 03:40:21 2024-06-14 pm EDT | ||
| 36.16 EUR | +0.06% |
|
| Current month | +2.15% | ||
| 1 month | -3.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 36.16 | +0.06% |
| 24-06-13 | 36.14 | -1.04% |
| 24-06-12 | 36.52 | -1.06% |
| 24-06-11 | 36.91 | +0.71% |
| 24-06-10 | 36.65 | +2.12% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:40 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN7LAQ |
| ISIN | DE000PN7LAQ3 |
| Date issued | 2023-08-21 |
| Maturity | 2024-12-20 (187 Days) |
| Parity | 1 : 1 |
| Emission price | 37.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.47 € |
|---|---|
| Lowest since issue | 34.83 € |
| Spread | 0.05 € |
| Spread % | 0.14% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
